Short Interest in MDxHealth SA (NASDAQ:MDXH) Increases By 140.1%

MDxHealth SA (NASDAQ:MDXH) saw a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 38,900 shares, a growth of 140.1% from the November 15th total of 16,200 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 141,500 shares, the short-interest ratio is presently 0.3 days.

Institutional Investors Weigh In On MDxHealth

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Perkins Capital Management Inc. lifted its stake in shares of MDxHealth by 70.7% during the third quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock valued at $1,555,000 after acquiring an additional 309,500 shares during the period. MVM Partners LLC raised its holdings in MDxHealth by 3.3% during the 3rd quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock worth $9,706,000 after purchasing an additional 150,000 shares during the last quarter. OneDigital Investment Advisors LLC raised its holdings in MDxHealth by 15.3% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after purchasing an additional 7,656 shares during the last quarter. Finally, Maven Securities LTD acquired a new position in MDxHealth during the 3rd quarter valued at about $208,000.

MDxHealth Trading Up 1.7 %

MDXH stock traded up $0.04 during trading on Friday, hitting $2.40. The company had a trading volume of 25,751 shares, compared to its average volume of 77,338. The firm has a 50-day moving average price of $1.99 and a 200-day moving average price of $2.44. MDxHealth has a 12 month low of $1.55 and a 12 month high of $4.64. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14. The stock has a market cap of $3.74 million, a price-to-earnings ratio of -1.58 and a beta of 1.42.

Analyst Ratings Changes

Several brokerages have issued reports on MDXH. Piper Sandler cut their price objective on MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. Lake Street Capital assumed coverage on MDxHealth in a report on Thursday, October 31st. They issued a “buy” rating and a $7.00 price target for the company.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.